cetrorelix


Also found in: Wikipedia.

cetrorelix

 [set″ro-rel´iks]
a gonadotropin-releasing hormone antagonist, used to inhibit premature luteinizing hormone surges in women undergoing controlled ovarian stimulation during infertility treatment; administered subcutaneously.

cetrorelix

/cet·ro·rel·ix/ (set″ro-rel´iks) a gonadotropin-releasing hormone antagonist, used as the acetate salt to inhibit premature surges of luteinizing hormone in women undergoing controlled ovarian stimulation during infertility treatment.

cetrorelix

[set′rorel′iks]
a gonadotropin-releasing hormone antagonist used to inhibit premature luteinizing hormone surges in women undergoing controlled ovarian stimulation during infertility treatment, administered subcutaneously.
References in periodicals archive ?
25 mg of cetrorelix was administered on days 1, 2 of gonadotropin stimulation and when at least 2 follicles reached 13-14 mm, it was started again and continued until HCG administration.
The second group (N=501) included all patients during the same period who did not have a diagnosis of PCOS but did require controlled ovulation induction using a cetrorelix regimen (cetrorelix-non-PCOS group).
25 mg of the GnRH antagonist cetrorelix (Cetrotide) or a midluteal daily injection of 0.
The company's shares, which have plunged 75% in the past nine months on the disappointing cetrorelix trial results, closed the week up 3 cents at 83 cents.
A new approach to the medical management of lower urinary tract symptoms (LUTS) secondary to BPH involves using a gonadotropin-releasing hormone (GnRH) antagonist such as cetrorelix.
Inhibition of growth of human ovarian cancer in nude mice by luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75).
today announced the release of Cetrotide (generic name: Cetrorelix acetate), indicated for the prevention of premature ovulation.
Cetrorelix is also in late-stage clinical development for endometriosis and benign prostate hyperplasia.
Meanwhile, the failure of AEterna Zentaris's cetrorelix to meet Phase III efficacy endpoints signals the end of gonadotropin-releasing hormones being approved for BPH.
Cetrorelix acetate (LHRH antagonist) was approved by FDA for clinical use in IVF programs.
Tokyo, Japan, Sept 21, 2006 - (JCN) - Shionogi and Nippon Kayaku announced on September 21 the launch in Japan of Cetrotide - cetrorelix acetate, for prevention of premature ovulation during
The current WH disorder therapeutics pipeline is promising with a strong line-up of first-in-class molecules in late stages of clinical development such as Pristiq, Aprela, Menerba, Elagolix and Cetrorelix.